The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront treatments at diagnosis, maintenance therapy, relapse information, and an update on clinical trials. A member of the IMF Nurse Leadership Board will talk about managing side effects and symptoms of myeloma and its treatments. After each presentation with the experts, attendees will have ample time to ask questions.

Myeloma 101 and Frontline Therapy

Joseph Mikhael, MD, MEd, FRCPC, FACP reviews multiple myeloma basics including what myeloma is, common symptoms and side effects, advances in how myeloma is initially diagnosed, the stages of myeloma treatment, induction therapy, transplant, and more. 

Relapsed Therapy and Clinical Trials

Joseph Mikhael, MD, MEd, FRCPC, FACP discusses the types of relapsed disease, what doctors consider when selecting a treatment regimen, relapsed/refractory treatment options, how doctors treat triple and penta-class refractory myeloma, updates on clinical trials, and more. 

Taking the Reins of Your Myeloma Care

Kevin Brigle, PhD, ANP (IMF Nurse Leadership Board) discusses how patients can manage myeloma-related symptoms and side effects along with side effects brought on by treatment. She outlines the most common side effects for each myeloma drug category, how to prevent infection, and more.

Additional Resources:

Download the IMF's Multiple Myeloma Informational Booklets:

Download IMF publications (https://www.myeloma.org/cancer-information-series)

What Is a Clinical Trial? (https://www.myeloma.org/clinical-trials)

*Of note, Venetoclax has already been approved to treat acute myeloid leukemia, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults and is now being evaluated to treat other types of cancers, including multiple myeloma. It is part of a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors that work by blocking the action of BCL-2 (a protein in the body that regulates cell death). Trials using Venetoclax were discussed in this webinar. You can learn about these three trials at the following links:

• CANOVA Clinical Trial Fact Sheet (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax%20CANOVA_M13-494_NCT03539744_a3.pdf)
  clinicaltrials.gov Identifier: NCT03539744
• Phase II Relapsed or Refractory Venetoclax Trial  (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax_M15-338_NCT02899052_a3.pdf)
  clinicaltrials.gov Identifier: NCT02899052
• Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib  (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax_M15-654_NCT03314181_a3.pdf)
  clinicaltrials.gov Identifier: NCT03314181

Workshop Sponsors:

With Support From: Abbvie, Amgen, Bristol Myers Squibb, GSK, Johnson & Johnson, Karyopharm, Sanofi and Takeda Oncology

(The IMF is not responsible for content provided by the links below and you may be subject to the Privacy Policy and Terms & Conditions of the destination site(s).)

	Even the Odds (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-04/AMGEN-Even-the-Odds.pdf)
	Revlimid Treatment Overview brochure (https://media.revlimid.com/wp-content/uploads/2020/01/US-REV-19-0673-REVLIMID-Treatment-Overview-Brochure.pdf) POM My Disease and Treatment (pomalyst.com) (https://www.pomalyst.com/assets/commercial/us/pomalystdtc/en/pdf/POM-My-Disease-and-Treatment-2204-US-2100028.pdf) Harness your power to fight MM with ABECMA® (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-06/BMS%20for%20Table%20Top%20-%20Abecma%20Patient%20Brochure.pdf)
	KaryForward, Patient Support Program (https://www.karyforward.com/assets/pdf/English_KF_Patient_Flyer_Sept2021.pdf) KaryForward, Patient Support Program, Espanol (https://www.karyforward.com/assets/pdf/Spanish_KF_Patient_Flyer_Feb2022_final.pdf) Patient and Caregiver Brochure (https://www.xpovio.com/content/pdf/mm/XPOVIO_Patient_and_Caregiver_Brochure.pdf) Treatment Experience Guide (https://www.xpovio.com/content/pdf/mm/Patient-Treatment-Experience-3.23.pdf)
	SARCLISA® (isatuximab-irfc) | A Targeted Immunotherapy (https://www.sarclisa.com/) CareASSIST: Helping eligible patients access their prescribed medications, CareASSIST for Sanofi medications | Patient Site (sanoficareassist.com) (https://www.sanoficareassist.com/)
	Multiple Myeloma Relapse Guide - NINLARO® (ixazomib) (https://www.ninlaro.com/sites/default/files/resources/ninlaro-patient-relapse-brochure.pdf) Understanding your Multiple Myeloma Lab Tests (ninlaro.com) (https://www.ninlaro.com/sites/default/files/2022-12/understanding_multiple_myeloma_lab_tests.pdf) Working with Your Care Team (ninlaro.com) (https://www.ninlaro.com/sites/default/files/2022-12/ninlaro_patient-_conversation_starter.pdf)